EGFR and non-small cell lung carcinoma: recently showed that EGFR-TKIs elicits interferon response in EGFR-mutant NSCLC, which is associated with improved therapeutic outcome (6), suggesting immune activation is critical for the therapeutic efficacy of EGFR-TKIs.